key: cord-0966932-5vgk77d3
authors: Seiglie, Jacqueline; Platt, Jesse; Cromer, Sara Jane; Bunda, Bridget; Foulkes, Andrea S.; Bassett, Ingrid V.; Hsu, John; Meigs, James B.; Leong, Aaron; Putman, Melissa S.; Triant, Virginia A.; Wexler, Deborah J.; Manne-Goehler, Jennifer
title: Diabetes as a Risk Factor for Poor Early Outcomes in Patients Hospitalized With COVID-19
date: 2020-08-26
journal: Diabetes Care
DOI: 10.2337/dc20-1506
sha: 0a53e02126c49ec40c3a41e58dfc41227738ddbd
doc_id: 966932
cord_uid: 5vgk77d3

OBJECTIVE: Diabetes and obesity are highly prevalent among hospitalized patients with coronavirus disease 2019 (COVID-19), but little is known about their contributions to early COVID-19 outcomes. We tested the hypothesis that diabetes is a risk factor for poor early outcomes, after adjustment for obesity, among a cohort of patients hospitalized with COVID-19. RESEARCH DESIGN AND METHODS: We used data from the Massachusetts General Hospital (MGH) COVID-19 Data Registry of patients hospitalized with COVID-19 between 11 March 2020 and 30 April 2020. Primary outcomes were admission to the intensive care unit (ICU), need for mechanical ventilation, and death within 14 days of presentation to care. Logistic regression models were adjusted for demographic characteristics, obesity, and relevant comorbidities. RESULTS: Among 450 patients, 178 (39.6%) had diabetes—mostly type 2 diabetes. Among patients with diabetes versus patients without diabetes, a higher proportion was admitted to the ICU (42.1% vs. 29.8%, respectively, P = 0.007), required mechanical ventilation (37.1% vs. 23.2%, P = 0.001), and died (15.9% vs. 7.9%, P = 0.009). In multivariable logistic regression models, diabetes was associated with greater odds of ICU admission (odds ratio 1.59 [95% CI 1.01–2.52]), mechanical ventilation (1.97 [1.21–3.20]), and death (2.02 [1.01–4.03]) at 14 days. Obesity was associated with greater odds of ICU admission (2.16 [1.20–3.88]) and mechanical ventilation (2.13 [1.14–4.00]) but not with death. CONCLUSIONS: Among hospitalized patients with COVID-19, diabetes was associated with poor early outcomes, after adjustment for obesity. These findings can help inform patient-centered care decision making for people with diabetes at risk for COVID-19.

July 2020 (9) . The convergence of these two epidemics has raised critical questions about the relationship between diabetes and COVID-19 severity (10, 11) , particularly in light of the increasing recognition that obesity, which is also highly prevalent in the U.S., is also a strong risk factor for severe COVID-19 (12) (13) (14) .

Consistent with early reports emerging from China (15, 16) , several U.S. studies have confirmed a high prevalence of diabetes and obesity among hospitalized patients with COVID-19 (4, 13, 17) . However, few studies have evaluated whether patients with diabetes who are hospitalized with COVID-19 are more likely to experience poor early outcomes (4, 11) and whether this association remains after adjustment for obesity status (4, 13) . Given that ;61% of people with diabetes in the U.S. have obesity (1) , understanding the contribution of these comorbidities to early outcomes among people hospitalized with COVID-19 is critically important to inform patient-centered care decision making for people with these conditions. In this study, we tested the hypothesis that diabetes is associated with poor early outcomes of hospitalization with COVID-19, even after obesity and other relevant clinical characteristics are accounted for.

This study used data from the Massachusetts General Hospital (MGH) COVID-19 Data Registry. Patients were eligible for inclusion in the registry if they presented to care (defined as the first contact with the health care system with COVID-19 symptoms) and were subsequently hospitalized at MGH with PCRconfirmed SARS-CoV-2 infection between 11 March 2020 and 30 April 2020. Over the study period, MGH had the highest total number of hospitalized patients with COVID-19 in Massachusetts, which in turn has had one of the largest COVID-19 case numbers in the U.S. as of June 2020 (9, 18) . All patients included in our study were followed for 14 days from the date of initial presentation to care with COVID-19. General inpatient diabetes at MGH is managed mostly by the primary medical team with basal-bolus supplemental insulin or supplemental insulin alone for mild hyperglycemia, whereas insulin drips are favored in the intensive care unit (ICU) setting. Specialty consultation is widely available for challenging cases.

Additional registry data were collected by performance of manual chart review for key aspects of the past medical history and details of the hospitalization. Chart review was performed by physicians and research nurses and their assistants. All members of the chart review team underwent detailed training on the standard operating procedure for data extraction, which was also subjected to quality checks to ensure data accuracy and minimize missing variables. In addition, height, weight, and BMI as well as hemoglobin A 1c (HbA 1c ) obtained during the hospitalization and blood glucose at admission during the index hospitalization were obtained electronically through the Enterprise Data Warehouse (EDW), a repository that was derived from the Epic electronic medical records system. For patients with diabetes who did not have an HbA 1c measured during the index hospitalization, we obtained HbA 1c values directly from the historical electronic medical record if available within the year preceding the index hospitalization for inclusion in a subgroup analysis of the relationship between baseline glycemic control and 14-day outcomes. The registry and this research were approved by the Partners HealthCare Institutional Review Board (protocol number 2020P000829).

Diabetes was defined based on the following criteria: 1) past medical history of diabetes as documented in the medical record and manually retrieved on chart review, 2) HbA 1c $6.5% during the index hospitalization, or 3) random blood glucose $200 mg/dL at admission to the hospital with supportive history by chart review. Only four individuals had a presenting random blood glucose of $200 mg/dL in the absence of a recent elevated HbA 1c or chart review diagnosis of diabetes. Two endocrinologists adjudicated these cases and determined that two of the four individuals had diabetes. The distribution of diabetes diagnoses based on these criteria is provided in the Supplementary Materials (p. 2). BMI, defined as weight in kilograms divided by the square of height in meters, was available from the EDW and was defined using standard BMI thresholds of ,18.5 kg/m 2 for underweight, 18.5-24.9 kg/m 2 for normal weight, 25.0-29.9 kg/m 2 for overweight, and $30.0 kg/m 2 for obese.

Additional analyses with subcategorization of the BMI $30.0 kg/m 2 group into $30.0-34.9 kg/m 2 and $35.0 kg/m 2 are provided in the Supplementary Materials (p. 7). Models were adjusted for race/ ethnicity (available from the EDW based on self-report) and defined as non-Hispanic White, non-Hispanic African American, Hispanic, other, and unknown. Finally, we manually extracted comorbidities that have commonly been reported among hospitalized patients with COVID-19 (17): coronary artery disease (CAD) or myocardial infarction (MI), congestive heart failure (CHF) (including both heart failure with preserved ejection fraction and heart failure with reduced ejection fraction), hypertension, renal disease, liver disease, chronic obstructive pulmonary disease (COPD) or asthma, and active malignancy, using standard clinical diagnostic criteria.

The primary outcomes in this study were 1) admission to the ICU, 2) need for mechanical ventilation, and 3) death among hospitalized patients with COVID-19 within 14 days of presentation to care. These states were not mutually exclusive, so an individual could experience more than one of these outcomes within the 14-day period. The exposure of interest was diabetes as defined above and, as a secondary exposure of interest, BMI category. We first described differences in the demographic and health characteristics by diabetes status. We used t tests to compare means and x 2 tests to compare proportions. We then stratified the cohort by diabetes status and BMI category and compared the proportions of people with and without diabetes within each BMI category for all three outcomes using x 2 tests. To test the hypothesis that poor baseline glycemic control would be associated with severe COVID-19, we conducted a subanalysis of the group with diabetes and compared the proportion of people by outcome according to HbA 1c values obtained either during the hospitalization if available or using the most recent value available in the year preceding the index hospitalization. HbA 1c was categorized as poor glycemic control (HbA 1c .9.0% according to HEDIS definition [19]) versus better glycemic control: #7.0% and .7.0-9.0%. Lastly, we conducted univariate and multivariable logistic regression to evaluate the association of diabetes, BMI category, and each of the primary outcomes. Multivariable models were additionally adjusted for age, sex, race/ethnicity, and comorbidities. Given that there were individuals who died prior to being mechanically ventilated, we conducted sensitivity analyses that excluded these individuals as well as a composite outcome "mechanical ventilation or death," which we provide in the Supplementary Materials (p.6). In all analyses, results were considered statistically significant if the corresponding P value was ,0.05. Analyses were conducted in Stata v. 15.1.

This article reports on 450 people who were eligible for inclusion in the MGH COVID-19 Data Registry and were hospitalized at MGH with SARS-CoV-2 infection between 11 March 2020 and 30 April 2020. The baseline characteristics of the study population are summarized in Table 1 . Of the 450 patients, 178 (39.6%) had diabetes, the vast majority of which was type 2 diabetes (mean HbA 1c 8.1%). Patients with diabetes were older than those without diabetes (mean age 66.7 vs. 61.6 years), and 42.1% of patients with diabetes were age $70 years (Table 1 ). There was a higher proportion of patients with diabetes who had obesity (51.4%, x 2 df 5 2 5 9.6, P 5 0.008) compared with the proportion of those without diabetes (36.8%). A higher proportion of patients with diabetes had a past medical history of CHF, hypertension, and renal disease compared with the proportion of patients without diabetes (Table 1) .

There were 156 ICU admissions, 129 people who required mechanical ventilation, and 49 deaths during the first 14 days after presentation to care. Among patients with diabetes versus patients without diabetes, a higher proportion was admitted to the ICU (42.1% vs. 29.8%, respectively, x 2 df 5 1 5 7.3, P 5 0.007), had mechanical ventilation (37.1% vs. 23.2%, x 2 df 5 1 5 10.2, P 5 0.001), or died (15.9% vs 7.9%, x 2 df 5 1 5 6.8, P 5 0.009) over this time horizon (Fig. 1) . The numerical counts for patients requiring ICU admission and mechanical ventilation were higher for people with diabetes than for people without diabetes within each BMI category, but pairwise comparisons of the proportions did not achieve statistical significance (Fig. 2) . In a subanalysis of people with diabetes and HbA 1c (n 5 168), the proportion of people who required ICU admission and mechanical ventilation was greater among people with HbA 1c .9.0 (52.5% and 47.5%, respectively) than among people with HbA 1c .7.0-9.0% (40.3% and 36.1%, respectively) and #7.0% (41.4% and 33.9%, respectively), but the differences did not achieve statistical significance at the 0.05 level ( 

In this observational study of 450 patients hospitalized with COVID-19, we found that compared with proportions of patients without diabetes, greater proportions of patients with diabetes were admitted to the ICU, required mechanical ventilation, and died within 14 days of presentation to care. We also found that diabetes was associated with 1.6-fold increased odds of ICU admission, 2.0-fold increased odds of mechanical ventilation, and 2.0-fold increased odds of death within 14 days from presentation to care, after adjustment for obesity. These findings add to the growing body of literature about the relationship of diabetes, obesity, and COVID-19 severity among people hospitalized with COVID-19 in the U.S. and expand our current understanding of the contributions of these two conditions to early outcomes among people hospitalized with COVID-19. Given the high prevalence of diabetes and obesity in the U.S. (1) and the rapidly rising case numbers of COVID-19 (9), these findings have important implications for patient-centered care decision making for people with metabolic disease and COVID-19.

Several other important findings emerged from our analysis. First, we found that the proportion of people with and without diabetes who were admitted to the ICU and who required mechanical ventilation was higher in magnitude with increasing BMI category. We also found that obesity was associated with 2.2-fold increased odds of ICU admission and 2.1-fold increased odds of mechanical ventilation compared with normal weight, after adjustment for diabetes, age, sex, race/ ethnicity, and major comorbidities. These findings are consistent with numerous studies reporting that obesity is a strong risk factor for severe COVID-19 (12) (13) (14) and add to the current literature by showing that this association persists at lower BMI thresholds than previously reported in a U. S. population (4,13) .

Second, we did not find a significant difference in the association between poor baseline glycemic control, as measured by HbA 1c .9.0 at hospitalization or within the year prior to admission, and early outcomes in this cohort; however, the proportion of patients with severe COVID-19 was higher in magnitude among patients with poor glycemic control compared with that among patients with better glycemic control. Although there has been little study of prehospitalization HbA 1c and COVID-19 outcomes, mounting evidence suggests that poor glycemic control among hospitalized patients with COVID-19 is associated with adverse outcomes, including higher mortality (20-23). Since the lack of an association between baseline glycemic control and early outcomes may have been limited by sample size in our study, the question of whether baseline glycemic control is associated with poor early COVID-19 outcomes remains a critically important one in consideration of the implications for risk stratification for this patient population.

Third, we found that Hispanic ethnicity was associated with greater odds of mechanical ventilation. This finding is consistent with recent data showing that ethnic minorities in the U.S. have a greater risk of poor COVID-19 outcomes (24) (25) (26) (27) . However, understanding the relationship between race/ethnicity and COVID-19 severity requires a more complex framework than afforded by the scope of this analysis. Given the limited data on racial/ethnic disparities and COVID-19 severity, future studies are needed to better understand these findings. Finally, the lack of an association between other major comorbidities and COVID-19 severity is also consistent with most U.S.-based adjusted analyses to date (4,13) but may also be related to limited power, since these comorbidities were less common than diabetes and obesity in our sample.

Our findings are consistent with numerous studies that have reported a high prevalence of diabetes among people with severe COVID-19 (2, 4, 5, 7, 13, 15, 28, 29) and add to the growing literature regarding the intersection of these epidemics by showing that the relationship between diabetes and increased odds of three key measures of COVID-19 severity at 14 days remains after adjustment for obesity. While several international studies have analyzed the association between diabetes and severe COVID-19 (30, 31) , only a few studies have presented this association according to stratified outcomes among patients hospitalized with COVID-19 (32, 33) . In their cross-sectional analysis of 51,633 Mexican subjects with COVID-19, Bello-Chavolla et al. (30) showed that diabetes (self-reported in 18.3% of subjects) and obesity (self-reported in 20.7% of subjects) were associated with greater odds of hospitalization, ICU admission, and mechanical ventilation. With use of a mechanistic COVID-19 lethality score, early-onset diabetes (defined as diabetes among individuals younger than 40 years of age) also emerged as an important predictor of mortality (hazard ratio 2.86 [95% CI 2.19-3.76]). In a similar study of 50,411 Mexican individuals with COVID-19, Gutierrez and Bertozzi reported that diabetes was associated with a 1.21 odds of mechanical ventilation and 1.95 odds of death (32) . Although the effect size of these associations was larger in our study, it is possible that the risk was underestimated in the study by Gutierrez and Bertozzi due to use of self-reported diabetes diagnosis only and the possible misclassification of individuals without diabetes who in fact had diabetes.

Few studies evaluating the association between diabetes and COVID-19 severity have been published to date in a U.S. population. In a longitudinal cohort study of 2,729 patients hospitalized with COVID-19 in New York, Petrilli et al. (4) showed that diabetes and obesity ($40 kg/m 2 ) were associated with 1.2 and 1.5 increased odds of critical illness, respectively. However, Petrilli et al. defined critical illness as a composite of care in the ICU, use of mechanical ventilation, discharge to hospice, or death, thus capturing a composite outcome. While composite outcomes are based in an assumption that components have the same directional relationship with the treatment or exposure, our analysis suggests that components of this outcome may have different relationships with kg/m 2 was associated with poor COVID-19 outcomes (13) . Although diabetes did not emerge as a risk factor for severe COVID-19 in their study, the lack of an association may have been due to limitations of a small sample size of people with diabetes (n 5 79).

Aside from previously studied mechanisms that predispose people with diabetes to higher risk of infections, such as impaired immunity (33, 34) , several mechanisms have been proposed suggesting a specific association between diabetes and SARS-CoV-2 illness severity (2) . Rao, Lau, and So (35) showed that diabetes and related traits are associated with increased expression of ACE2, the receptor for SARS-CoV-2, which could influence susceptibility and severity of infection. In addition, cytokines may be another mechanistic link between diabetes and SARS-CoV-2 illness severity. For instance, interleukin-6 (IL-6), a pleiotropic cytokine that is increased in diabetes and metabolic disorders (10), has also emerged as a predictor of poor prognosis among people with COVID-19 (36) . However, because most studies are preliminary, additional work is needed to understand mechanisms underlying the association between diabetes and increased COVID-19 severity (7) .

One of the strengths of this study is that manual chart review allowed for detailed patient information to be incorporated into the analysis, including the adjudication of diabetes status by endocrinologists. However, this study had several limitations. First, the study was conducted at a single institution in Massachusetts, which had a different COVID-19 prevalence, rate of COVID-19 case increase, and ICU bed capacity (18) than the sites of other studies referenced here (4, 13) . Second, the sample size for this study was limited, which may have affected our ability to detect significant differences, especially in the association between prehospitalization glycemic control and the outcomes of interest. However, despite the small sample size, the completeness of data allowed us to rigorously evaluate the primary exposures, outcomes, and covariates, including medical comorbidities. Another important limitation is that people who died without escalation of care may have opted against admission to the ICU, for instance, due to do-not-resuscitate/do-not-intubate code status, hence reflecting their outcome in the context of their goals of care rather than as part of their course throughout the hospitalization with COVID-19. However, in sensitivity analyses that excluded these individuals and in one that included a composite outcome of mechanical ventilation or death, the magnitude and significance of the main associations reported remained. Lastly, the observational data and methodological approach used in this study identified potentially important associations but do not establish causal relationships.

The convergence of the diabetes and COVID-19 epidemics has raised critical concerns regarding the heightened illness severity associated with these conditions (10, 11) . This is a cause for particular concern in the U.S., where the prevalence of metabolic disease is high and may place many people at greater risk of developing severe COVID-19 should they become infected with SARS-CoV-2. In this study, we showed that diabetes was associated with poor early outcomes among hospitalized patients with COVID-19, after adjustment for obesity, which was also a strong risk factor for poor early outcomes. Our findings can help guide risk mitigation efforts and patient-centered care decision making for people with diabetes and obesity, particularly in areas of the U.S. with a high prevalence of diabetes and obesity that are in early phases of the SARS-CoV-2 outbreak. Future research is urgently needed to better understand the mechanisms underlying the relationship between diabetes, obesity, and COVID-19 severity and approaches to prevent and treat people with metabolic disease and COVID-19. 

Accessed 16

Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and metaanalysis

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Prevalence of diabetes mellitus in 2019 novel coronavirus: a metaanalysis

Characteristics and outcomes of COVID-19 positive patients with diabetes managed as outpatients

Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States

COVID-19) in the U.S.: Cases, Data & Surveillance: Cases in the

Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics

COVID-19in people with diabetes: urgently needed lessons from early reports

ObesityandCOVID-19 severity in a designated hospital in Shenzhen

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Obesity is a risk factor for greater COVID-19 severity

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study

Disparities in outcomes among COVID-19 patients in a large health care system in California

Social vulnerability and racial inequality in COVID-19 deaths in Chicago

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China

Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico

Non-communicable diseases and inequalities increase risk of death among COVID-19 patients in Mexico

Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement

The effect of short-term hyperglycemia on the innate immune system

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a Mendelian randomization analysis highlights tentative relevance of diabetes-related traits

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Acknowledgments. The authors thank the COVID-19 Data Registry Team at MGH for their leadership in creating this valuable resource. In particular, the authors thank the numerous manual chart reviewers and experienced data managers for their methodological expertise, time, and effort.